Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

Summary

This phase I trial studies the side effects and best dose of entinostat in treating pediatric patients with solid tumors that have come back or have not responded to treatment. Entinostat may block some of the enzymes needed for cell division and it may help to kill tumor cells.

Timeline

Start

2017-01-06

Primary completion

2021-06-30

Completion

2021-09-30

Drugs

Indications